Research programme: CD47/SIRPalpha pathway modulators - Sanquin/Synthon

Drug Profile

Research programme: CD47/SIRPalpha pathway modulators - Sanquin/Synthon

Alternative Names: CD47 antigen/SIRPalpha protein modulators; CD47-SIRPα modulators

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Synthon
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fragments; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action CD47 antigen modulators; SIRPA protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 Mar 2017 Sanquin Blood Supply Foundation exclusively licenses US 9 352 037 patent and its foreign family members, EP 2 282 772 patents to Synthon Biopharmaceuticals
  • 02 Mar 2017 Early research in Cancer in Netherlands (Parenteral) before March 2017
  • 02 Mar 2017 Synthon Biopharmaceuticals and Sanquin Blood Supply Foundation enter into a licence and collaboration agreement to develop immuno-oncology therapeutics modulating the CD47-SIRPα pathway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top